Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Three Kennedy Trust for Rheumatology Research (KTRR) Fellows at the Kennedy Institute were recently awarded prestigious funding awards, highlighting the success of the KTRR programme in supporting outstanding investigators launch their independent research career.

The KTRR Senior Research Fellowship programme creates a platform for early stage scientists to launch an independent research career; it has also enabled the Kennedy Institute to recruit bright young investigators from across the globe. 

“The KTRR provided a great opportunity for the Institute to recruit the best and brightest after the move to Oxford.” Says Professor Michael Dustin, Director of Research of the Kennedy Institute. “We are all excited by their progress in establishing their research programs and development as independent scientists.”

The five-year fellowships provide awardees with a generous funding package and strong mentorship, embedded within the institute’s outstanding research environment. 

The first of these fellowships was awarded in 2013 to Dr Tal Arnon, who has subsequently received a Wellcome Trust Investigator award in 2014.

Three more Senior Research Fellowships were awarded in 2016, to Dr Jelena Bezbradica Mirkovic, Dr Anjali Kusumbe, and Dr Audrey Gerard.

Dr Kusumbe received an MRC Career Development Fellowship in 2017 and earlier this year Dr Gerard won a BBSRC New Investigator Grant.

More recently, Dr Jelena Bezbradica Mirkovic won an MRC New Investigator Research Grant to study the biology of FAM26F protein in myeloid cells.

She says: “We are grateful to the Kennedy Trust for their support in establishing our independent research programmes. My group is investigating how innate immune cells, such as macrophages and dendritic cells, integrate tissue-derived inflammatory signals to initiate an appropriate effector response to infection or to sterile injury. The MRC New Investigator Grant is an exciting opportunity to investigate what role a poorly characterized protein, FAM26F, plays in the inflammatory process.”

 

Similar stories

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.